ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2026 • ACR Convergence 2022

    Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome

    Shruti Singh Kakan1, Yaping Ju2, Maria Edman2 and Sarah Hamm-Alvarez3, 1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 2Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 3Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA

    Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…
  • Abstract Number: 2028 • ACR Convergence 2022

    The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
  • Abstract Number: 1956 • ACR Convergence 2022

    Functional Disabilities in Hands Precede Those in Feet in Patients Progressing from Clinically Suspect Arthralgia to Rheumatoid Arthritis; A Longitudinal Observational Study

    Sarah J.H. Khidir1, Bastiaan van Dijk2, Marloes Verstappen1, Elise van Mulligen3 and Annette van der Helm-van Mil4, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre (LUMC), Leiden, Netherlands, 3Erasmus Medical Center, Leiden University Medical Center, Rotterdam, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: In the pre-arthritis phase of Rheumatoid Arthritis (RA), symptoms resulting in physical disabilities already occur. It is unknown whether functional disabilities start in hands…
  • Abstract Number: 1955 • ACR Convergence 2022

    Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients

    Tomohiro Kameda1, shusaku nakashima2, Masayuki Inoo3, Ikuko Onishi3, Noriyuki Kurata3, Hiromi Shimada1, Risa Wakiya1, Mikiya Kato1, taichi miyagi4, Yusuke Ushio5, Rina Mino6, Kanako Chujo7, norimitsu Kadowaki8 and Hiroaki Dobashi9, 1Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 3Utazu Hospital, Yayauta-gun, Japan, 4Kagawa University, Kidagun, Japan, 5Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 6Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, 7Kagawa University, Miki, Kita District, Kagawa, Japan, 8Kagawa University, Kita-Gun, Japan, 9Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan

    Background/Purpose: Lymphoproliferative disorders (LPDs), including malignant lymphoma, are known to occur in RA patients treated with disease modified antirheumatic drugs (DMARDs). In particular, LPD associated…
  • Abstract Number: 2011 • ACR Convergence 2022

    More Meticulously Following Treat-to-target in RA Does Not Lead to Less Radiographic Progression: A Longitudinal Analysis in BIODAM

    Sofia Ramiro1, Robert Landewé2, Désirée van der Heijde3, Alexandre Sepriano4, Oliver FitzGerald5, Mikkel Østergaard6, Joanne Homik7, Ori Elkayam8, Carter Thorne9, Maggie Larche10, Gianfranco Ferraccioli11, Marina Backhaus12, Gilles Boire13, Bernard Combe14, Thierry Schaeverbeke15, Alain Saraux16, Maxime Dougados17, Maurizio Rossini18, Marcello Govoni19, Luigi Sinigaglia20, Alain Cantagrel21, CF Allaart1, Cheryl Barnabe22, Clifton O. Bingham III23, Dirkjan van Schaardenburg24, HIlde Hammer25, Rana Dadashova26, Edna Hutchings26, Joel Paschke26 and Walter P Maksymowych27, 1Leiden University Medical Center, Leiden, Netherlands, 2Amsterdam University Medical Center, Meerssen, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 4Leiden University Medical Centre, Portela Loures, Portugal, 5Conway Institute, University College Dublin, Dublin, Ireland, 6Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 7Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 8Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 9Southlake Regional Health Centre, Newmarket, ON, Canada, 10McMaster University, Hamilton, ON, Canada, 11Catholic University of the Sacred Heart, Rome, Roma, Italy, 12Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, 13Universite de Sherbrooke, Sherbrooke, QC, Canada, 14CHU Montpellier and Montpellier University, Monpellier, France, 15FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, 16CHU Brest, Brest, France, 17Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, 18Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, 19S. Anna Hospital and University of Ferrara, Ferrara, Italy, 20Gaetano Pini Institute, Milano, Italy, 21CHU Toulouse, Paul Sabatier University, Toulouse, France, 22University of Calgary, Calgary, AB, Canada, 23Johns Hopkins University, Baltimore, MD, 24Amsterdam UMC, Amsterdam, Netherlands, 25Diakonhjemmet Hospital, Oslo, Oslo, Norway, 26CARE Arthritis LTD, Edmonton, AB, Canada, 27Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have…
  • Abstract Number: 1954 • ACR Convergence 2022

    Development of the Patient-Important Outcomes Data Repository (PIONEER) for Rheumatic Diseases; An Enhanced Database Combining Electronic Medical Data with Insight from Chart Reviews

    Simon Helfgott1, Kent Kwas Huston2, Jasvinder singh3, Nehad Soloman4, Jeremy Broestl5, Kimmi Cox5, Kelsey Milligan5 and Colin Edgerton6, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, 3University of Alabama at Birmingham, Birmingham, AL, 4Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, 5Trio Health, Louisville, CO, 6Articularis Healthcare, Sullivans Island, SC

    Background/Purpose: Clinical and non-clinical forces contribute to real-world treatment effectiveness, yet most studies focus on efficacy in an idealized setting. To identify factors impacting clinical…
  • Abstract Number: 1424 • ACR Convergence 2022

    Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

    Joanna KEDRA1, Lina El Houari1, Florence Tubach1, Benjamin granger1 and Bruno Fautrel2, 1Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 2Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 1430 • ACR Convergence 2022

    Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

    Cristiano Moura1, Luck Lukusa1, Laura Yan1, Walter P Maksymowych2, Denis Choquette3, Gilles Boire4 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada

    Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
  • Abstract Number: 1951 • ACR Convergence 2022

    Interleukin 1 Receptor Antagonist Relation to Cardiovascular Disease in Patients with Rheumatoid Arthritis

    Claudia De Luis zarate1, Cristina Almeida Santiago2, Maria Vanesa Hernández Hernández3, antonia De Vera González4, Alejandra González Delgado4, Juan Carlos Quevedo Abeledo5 and Ivan Ferraz Amaro6, 1Hospital Universitario de Canarias, Puerto de la Cruz, Spain, 2Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 3HUC, San Cristóbal de la, Spain, 4HOSPITAL UNIVERSITARIO DE CANARIAS, Santa Cruz de Tenerife, Spain, 5Hospital Universitario Dr. Negrín, Santa Cruz de Tenerife, Spain, 6Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain

    Background/Purpose: Interleukin (IL) 1, and its family member, IL-1 receptor antagonist (IL-1ra), are involved in the pathogenesis and inflammation perpetuation of patients with rheumatoid arthritis…
  • Abstract Number: 2021 • ACR Convergence 2022

    Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome

    Xiaomei Shan1, Clara Reichardt1, Jeeshan Singh1, Anne Zeitler2, Christine Schauer1, Jasmin Knopf1, Martin Herrmann1, Gerhard Grossmayer1, Georg Schett1 and Luis Munoz1, 1Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany

    Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
  • Abstract Number: 1966 • ACR Convergence 2022

    Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
  • Abstract Number: 1970 • ACR Convergence 2022

    Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies

    Clarice P. Lin1 and Richard C. Chou2, 1University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, 2University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY

    Background/Purpose: Recent clinical practice has increasingly utilized musculoskeletal (MS) ultrasound studies to assess inflammation and soft-tissue abnormalities of the joints, such as synovitis and bone…
  • Abstract Number: 1949 • ACR Convergence 2022

    Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases

    amit ziv1, Merav Heshin-Bekenstein2, Ruby Haviv3, Shaye Kivity4, doron netzer5, shlomit yaron5, yoav schur5, tsipi egert6, yona egert6, yaron sela7, Philip Hashkes8 and Yosef Uziel9, 1Meir Hospital, Kfar Saba, Israel, 2Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 3Meir Medical Center, Ra'Anana, Israel, 4Meir Medical Center, Kefar Saba, Israel, 5Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel, 6Inbar, NPO, Ramat Gan, Israel, 7The Research Center for Internet Psychology, School of Communications, Reichman University, Herzliya, Israel, 8Shaare Zedek Medical Center, Jerusalem, Israel, 9Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel

    Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients…
  • Abstract Number: 1961 • ACR Convergence 2022

    COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age

    Holly Dudley1, megan O'Mara2, Ann Auma1, Jenny Gong3, Yael Ross4, Natalie Gurevich2, Larraine Gordesky5, Nora Singer6, Lenche Kostadinova7, Brigid Wilson7, David Zidar7, Christopher King1, David Canaday1, Carey Shive1, Maya Mattar8 and Donald Anthony9, 1Case Western Reserve University, Cleveland, OH, 2Cleveland Veteran Affairs Medical Center, Cleveland, OH, 3Case Western School of Medicine, Cleveland, OH, 4Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, 5MetroHealth Medical Center, Cleveland, OH, 6The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, 7VA Medical Center, Cleveland, OH, 8Louis Stokes VA Medical Center, Mayfield Heights, OH, 9Case, VA, Metro, Chardon, OH

    Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19…
  • Abstract Number: 1422 • ACR Convergence 2022

    Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice

    Louis Bessette1, Proton Rahman2, John Kelsall3, Jane Purvis4, Emmanouil Rampakakis5, Allen J. Lehman6, Meagan Rachich7, Francois Nantel8, A. Marilise Marrache9 and Odalis Asin-Milan10, 1Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 2Memorial University, St. John's, NL, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Peterborough Education, Peterborough, ON, Canada, 5McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7Janssen Inc., Guelph, ON, Canada, 8Nantel MedSci Consult, Montréal, QC, Canada, 9Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 10Janssen Canada, Laval, QC, Canada

    Background/Purpose: Although biologic use in RA has a well-characterized infections risk factor, most studies were done on 1st-generation anti-tumor necrosis factor (TNFi) drugs or post-drug…
  • « Previous Page
  • 1
  • …
  • 448
  • 449
  • 450
  • 451
  • 452
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology